22
Participants
Start Date
October 21, 2024
Primary Completion Date
December 31, 2027
Study Completion Date
July 30, 2028
Large fraction radiotherapy in combined with GM-CSF, Lenalidomide, and Glofitamab
"Large fraction radiotherapy is administered at 5Gy/day for 3 days, with one to two courses carried out on a single target lesion as determined by the investigator. Granulocyte-macrophage colony-stimulating factor (GM-CSF) is administered at 400µg per day for 3 days starting on the first day after the end of radiotherapy. Lenalidomide is administered at 25mg per day for 14 days starting on the first day after the end of radiotherapy. Glofitamab is administered starting on the 7th day after the end of radiotherapy.~For cycles 2-6, each cycle is 21 days. GM-CSF is administered at 400µg per day for 3 days starting on the first day of each cycle. Glofitamab is administered at 30mg on the 4th day of each cycle. Lenalidomide is administered at 25mg per day for 14 days starting on the first day. Treatment consists of 6 cycles or until disease progression, death, intolerable toxicity, withdrawal of informed consent."
RECRUITING
The First Affiliated Hospital of Xiamen University, Xiamen
The First Affiliated Hospital of Xiamen University
OTHER